drugset / Trial / NCT04665076
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Unknown
60 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, non-randomized, single-arm, open clinical trial.
Timeline
- Start
- 2020-10-22
- Primary completion
- 2023-10-21
- Completion
- 2025-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Auto CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |